Don't forget CTIX Europe! CTIX management said it is in discussions with a flagship university in Europe to conduct clinical trials on Kevetrin, the Company’s flagship anti-cancer compound.

The university wants to test Kevetrin as a combination therapy for leukemia with drugs proprietary to one of the world’s largest pharmaceutical companies. A confidentiality agreement, prevents CTIX from identifying the University or the pharmaceutical company at this time.

“It seems that the potential of Kevetrin is starting to circle the globe. This University has a distinguished reputation in hematological diseases,” said Dr. Krishna Menon, Chief Scientific Officer at Cellceutix.

“Our patent has been published. Only when a compound looks extremely promising do major pharmaceutical companies and universities approach a smaller company like Cellceutix. This gives us a great sense of confirmation as to the potential of Kevetrin and validation in our beliefs about the possible robust number of indications where it could provide a therapeutic benefit.”